Bausch Health Companies Inc. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
Bausch Health Companies Inc. (BHC) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $19.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2026-07-30
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-06-30 was $8.00M, a 14.29% increase year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2026-03-31 was $11.00M, a 22.22% increase year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-12-31 was $10.00M, a 0.00% change year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2025-09-30 was $8.00M, a 20.00% decline year-over-year.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2025 was $34.00M, a 8.11% decline from fiscal 2024.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2024 was $37.00M, a 19.57% decline from fiscal 2023.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2023 was $46.00M, a 64.29% increase from fiscal 2022.
- Bausch Health Companies Inc. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2022 was $28.00M, a 71.72% decline from fiscal 2021.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $19.00M 10-Q · filed 2026-07-30 | $29.00M derived: sum of 3 quarters · filed 2026-07-30 | $37.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $11.00M 10-Q · filed 2026-04-30 | $21.00M derived: sum of 2 quarters · filed 2026-04-30 | $29.00M derived: sum of 3 quarters · filed 2026-04-30 | $36.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $18.00M derived: sum of 2 quarters · filed 2026-02-19 | $25.00M derived: sum of 3 quarters · filed 2026-07-30 | $34.00M 10-K · filed 2026-02-19 | |
| 2025-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $15.00M derived: sum of 2 quarters · filed 2026-07-30 | $24.00M 10-Q · filed 2025-10-30 | $34.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $16.00M 10-Q · filed 2026-07-30 | $26.00M derived: sum of 3 quarters · filed 2026-07-30 | $36.00M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $9.00M 10-Q · filed 2026-04-30 | $19.00M derived: sum of 2 quarters · filed 2026-04-30 | $29.00M derived: sum of 3 quarters · filed 2026-04-30 | $37.00M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $20.00M derived: sum of 2 quarters · filed 2026-02-19 | $28.00M derived: sum of 3 quarters · filed 2026-02-19 | $37.00M 10-K · filed 2026-02-19 | |
| 2024-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $18.00M derived: sum of 2 quarters · filed 2025-10-30 | $27.00M 10-Q · filed 2025-10-30 | $51.00M derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $17.00M 10-Q · filed 2025-07-31 | $41.00M derived: sum of 3 quarters · filed 2025-07-31 | $49.00M derived: sum of 4 quarters · filed 2025-07-31 | |
| 2024-03-31 | $9.00M 10-Q · filed 2025-05-01 | $33.00M derived: sum of 2 quarters · filed 2025-05-01 | $41.00M derived: sum of 3 quarters · filed 2025-05-01 | $47.00M derived: sum of 4 quarters · filed 2025-05-01 | |
| 2023-12-31 | $24.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $32.00M derived: sum of 2 quarters · filed 2025-02-20 | $38.00M derived: sum of 3 quarters · filed 2025-02-20 | $46.00M 10-K · filed 2025-02-20 | |
| 2023-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $14.00M derived: sum of 2 quarters · filed 2024-10-31 | $22.00M 10-Q · filed 2024-10-31 | $31.00M derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $14.00M 10-Q · filed 2024-08-01 | $23.00M derived: sum of 3 quarters · filed 2024-08-01 | $28.00M derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | $8.00M 10-Q · filed 2024-05-02 | $17.00M derived: sum of 2 quarters · filed 2024-05-02 | $22.00M derived: sum of 3 quarters · filed 2024-05-02 | $28.00M derived: sum of 4 quarters · filed 2024-05-02 | |
| 2022-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $14.00M derived: sum of 2 quarters · filed 2024-02-22 | $20.00M derived: sum of 3 quarters · filed 2024-02-22 | $28.00M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $11.00M derived: sum of 2 quarters · filed 2023-11-02 | $19.00M 10-Q · filed 2023-11-02 | $25.00M derived: sum of 4 quarters · filed 2023-11-02 | |
| 2022-06-30 | $6.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $14.00M 10-Q · filed 2023-08-03 | $20.00M derived: sum of 3 quarters · filed 2023-08-03 | $64.00M derived: sum of 4 quarters · filed 2023-08-03 | |
| 2022-03-31 | $8.00M 10-Q · filed 2023-05-04 | $14.00M derived: sum of 2 quarters · filed 2023-05-04 | $58.00M derived: sum of 3 quarters · filed 2023-05-04 | $101.00M derived: sum of 4 quarters · filed 2023-05-04 | |
| 2021-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $50.00M derived: sum of 2 quarters · filed 2023-02-23 | $93.00M derived: sum of 3 quarters · filed 2023-02-23 | $99.00M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $44.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $87.00M derived: sum of 2 quarters · filed 2022-11-03 | $93.00M 10-Q · filed 2022-11-03 | $99.00M derived: sum of 4 quarters · filed 2022-11-03 | |
| 2021-06-30 | $43.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $49.00M 10-Q · filed 2022-08-09 | $55.00M derived: sum of 3 quarters · filed 2022-08-09 | $61.00M derived: sum of 4 quarters · filed 2022-08-09 | |
| 2021-03-31 | $6.00M 10-Q · filed 2022-05-10 | $12.00M derived: sum of 2 quarters · filed 2022-05-11 | $18.00M derived: sum of 3 quarters · filed 2022-05-11 | $25.00M derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | $6.00M derived: 8-K 12 month − 10-Q 9 month · filed 2022-05-11 | $12.00M derived: sum of 2 quarters · filed 2022-05-11 | $19.00M derived: sum of 3 quarters · filed 2022-05-11 | $36.00M 8-K · filed 2022-05-11 | |
| 2020-09-30 | $6.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $13.00M derived: sum of 2 quarters · filed 2021-11-02 | $30.00M 10-Q · filed 2021-11-02 | $38.00M derived: sum of 4 quarters · filed 2021-11-02 | |
| 2020-06-30 | $7.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $24.00M 10-Q · filed 2021-08-03 | $32.00M derived: sum of 3 quarters · filed 2021-08-03 | $40.00M derived: sum of 4 quarters · filed 2021-08-03 | |
| 2020-03-31 | $17.00M 10-Q · filed 2021-05-04 | $25.00M derived: sum of 2 quarters · filed 2021-05-04 | $33.00M derived: sum of 3 quarters · filed 2021-05-04 | $44.00M derived: sum of 4 quarters · filed 2021-05-04 | |
| 2019-12-31 | $8.00M derived: 8-K 12 month − 10-Q 9 month · filed 2021-05-04 | $16.00M derived: sum of 2 quarters · filed 2021-05-04 | $27.00M derived: sum of 3 quarters · filed 2021-05-04 | $36.00M 8-K · filed 2021-05-04 | |
| 2019-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-03 | $19.00M derived: sum of 2 quarters · filed 2020-11-03 | $28.00M 10-Q · filed 2020-11-03 | $39.00M derived: sum of 4 quarters · filed 2020-11-03 | |
| 2019-06-30 | $11.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $20.00M 10-Q · filed 2020-08-06 | $31.00M derived: sum of 3 quarters · filed 2020-08-06 | $39.00M derived: sum of 4 quarters · filed 2020-08-06 | |
| 2019-03-31 | $9.00M 10-Q · filed 2020-05-07 | $20.00M derived: sum of 2 quarters · filed 2020-05-07 | $28.00M derived: sum of 3 quarters · filed 2020-05-07 | $36.00M derived: sum of 4 quarters · filed 2020-05-07 | |
| 2018-12-31 | $11.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $19.00M derived: sum of 2 quarters · filed 2020-02-19 | $27.00M derived: sum of 3 quarters · filed 2020-02-19 | $39.00M 10-K · filed 2020-02-19 | |
| 2018-09-30 | $8.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04 | $16.00M derived: sum of 2 quarters · filed 2019-11-04 | $28.00M 10-Q · filed 2019-11-04 | $40.00M derived: sum of 4 quarters · filed 2019-11-04 | |
| 2018-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $20.00M 10-Q · filed 2019-08-06 | $32.00M derived: sum of 3 quarters · filed 2019-08-06 | $43.00M derived: sum of 4 quarters · filed 2019-08-06 | |
| 2018-03-31 | $12.00M 10-Q · filed 2019-05-06 | $24.00M derived: sum of 2 quarters · filed 2019-05-06 | $35.00M derived: sum of 3 quarters · filed 2019-05-06 | $52.00M derived: sum of 4 quarters · filed 2019-05-06 | |
| 2017-12-31 | $12.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $23.00M derived: sum of 2 quarters · filed 2019-02-20 | $40.00M derived: sum of 3 quarters · filed 2019-02-20 | $49.00M 10-K · filed 2019-02-20 | |
| 2017-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $28.00M derived: sum of 2 quarters · filed 2018-11-06 | $37.00M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $26.00M 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $9.00M 10-Q · filed 2017-05-09 | ||||
| 2016-12-31 | $175.00M 8-K · filed 2018-08-10 | ||||
| 2015-12-31 | $174.00M 10-K · filed 2017-03-01 | ||||
| 2014-12-31 | $116.80M 10-K · filed 2016-04-29 | ||||
| 2013-12-31 | $141.20M 10-K · filed 2015-02-25 | $141.18M 10-K · filed 2014-02-28 | |||
| 2012-12-31 | $106.25M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |